PDF下载 ( 120 KB)
Clinical study on the relationship between the apoptosis in hepatocellular carcinoma cells induced by cisplatin and the expression of Fas protein
-
摘要: 探讨顺铂 (CDDP)在人体内诱导肝癌细胞凋亡及其与Fas表达的关系。将 30例肝细胞性肝癌 (HCC)患者随机分成两组 :CDDP治疗组患者在术前行顺铂诱导治疗 (30mg/d ,静脉滴注 ,连续 4天 ) ;对照组则未给予任何化疗药物。流式细胞仪检测两组HCC患者手术标本的细胞凋亡 (APO) ;免疫组化 (SP法 )检测肿瘤组织Fas蛋白及p5 3蛋白的表达 ;并作相关性分析。CDDP组APO为 (7 72± 6 6 6 ) %较对照组明显增高 (t=4 0 9,P <0 0 1) ;CDDP组Fas的表达 (10 / 16 )明显高于对照组 (3/ 14 ,P <0 0 5 ) ;p5 3的表达在两组间无差异 (CDDP组 5 / 16例 ,对照组 4 / 14例 ,P >0 0 5 ) ;CDDP组中Fas与p5 3的表达无相关性 (P >0 0 5 )。CDDP在人体内能够诱导肝癌细胞凋亡而起治疗作用 ;其作用途径可能与Fas相关Abstract: To investigate the relationship between Fas and the apoptosis in hepatocellular carcinoma cells induced by cisplatin. Thirty patients with hepatocellular carcinoma were divided into 2 groups. Sixteen patients received intravenous cisplatin (CDDP) 30mg/day for 4 days preoperatively. whereas the other 14 did not receive any chemotherapy or radiotherapy, and served as controls. Hepatocellular carcinoma cell's apoptosis rate (APO) was examined by flow cytometry (FCM) . The expression of Fas and p53 were examined by immunohistochemical staining. Apoptosis of hepatocellular carcinoma cells increased significantly to 7.72±6.66% in the CDDP-treated group compared with the controls (0.35±0.92%, P<0.01) . Ten patients with Fas protein positive in CDDP-treated group (10/16) were significantly more than 3 positive patients in the controls (3/14, P<0.05) . About p53, there were 5 positive patients in CDDP-treated group and 4 in the controls. In CDDP-treated group, the expression of Fas had no relation with the expression of p53 protein (P>0.05) . Apoptosis in hepatocellular carcinoma cells were enhanced by intravenous infusion of cisplatin. The expression of Fas associated with the apoptosis in hepatocellular carcinoma cells caused by CDDP.
-
Key words:
- Fas /
- Apoptosis /
- Hepatocellular carcinoma /
- Cisplatin
-
[1] Qin LF, Ng IO. Induction of apoptosis by cisplatin and its effect on cell cycle-related proteins and cell cycle changes in hepatoma cells[J]. Cancer Lette, 2002, 175 (1) ∶27-38. [2] Ito Y, Takeda T, Umeshita K, et al. Fas antigen expression in hepatocellular carcinoma tissues[J].Oncol Rep, 1998, 5 (1) ∶41-4. [3]Fukuzawa K, Takahashi K, Furuta K, et al. Expression of Fas/Fas ligand (FasL) and its involvement in infiltrating lymphocytes in hepatocellular carcinoma (HCC) [J]. J Gastroenterol, 2001, 36 (10) ∶681-8. [4] Ito Y, Monden M, Takeda T, et al. The status of Fas and Fas ligand expression can predict recurrence of hepatocellular carcinoma[J].Br J Cancer, 2000, 82 (6) ∶1211-7. [5] Muller M, Strand S, Hug H, et al. Drug induced apoptosis in hepatoma cells is mediated by the CD95 (Ap0-1/Fas) receptor/ligand system and involves activation of wild-type p53[J].J Clin Invest, 1997, 99 (3) ∶403-13. [6]Shin EC, Shin WC, Choi Y, et al. Effect of interferon-gamma on the susceptibility to Fas (CD95/AP0-1) -mediated cell death in human hepatoma cells[J].Cancer Immunol Immunother, 2001, 50 (1) ∶23-30. [7] Lamboley C, Bringuier AF, Camus E, et al. Overexpression of the mouse Fas gene in human Hep3B hepatoma cells overcomes their resistance to Fas-mediated apoptosis[J].J Hepatol, 2002, 36 (3) ∶885-94. -
本文二维码
计量
- 文章访问数: 2304
- HTML全文浏览量: 11
- PDF下载量: 824
- 被引次数: 0
下载:
